Nipro (FRA:5FA) Asset Impairment Charge : €0 Mil (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Nipro Asset Impairment Charge?

Nipro's Asset Impairment Charge for the three months ended in Sep. 2024 was €0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2024 was €0 Mil.

Nipro Asset Impairment Charge Historical Data

The historical data trend for Nipro's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nipro Asset Impairment Charge Chart

Nipro Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Asset Impairment Charge

Get a 7-Day Free Trial

Nipro Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Nipro Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

Nipro Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Nipro's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Nipro Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nipro Corp (FRA:5FA) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

8086:Japan

Address

3-9-3 Honjo-Nishi Kita-ku, Osaka, JPN, 531-8510

Website

http://www.nipro.co.jp

Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.

Nipro Headlines

No Headlines